RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A disease progression model
Mader, G., Purser, M. F., Mladsi, D. M., Sanon, M., Oberdhan, D., Watnick, T., & Seliger, S. (2020). Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): A disease progression model. American Journal of Kidney Diseases, 75(4), 601. https://doi.org/10.1053/j.ajkd.2020.02.235
10.1053/j.ajkd.2020.02.001 National Kidney Foundation 2020 Spring Clinical Meeting Abstracts March 25-29, 2020 American Journal of Kidney Diseases, Vol. 75, Issue 4, p517–535 Published in issue: April 2020 233.
INTRODUCTION: The efficacy and safety of tolvaptan in adults with ADPKD was initially established in a 3-year phase 3 clinical trial (TEMPO 3:4; NCT00428948). Tolvaptan was approved in the United States in 2018 for patients with ADPKD at high risk of progression. A published ADPKD progression model predicted longer-term outcomes including eGFR decline and time to ESRD. The model incorporated an equation used to predict eGFR based on Mayo subclasses 1C, 1D, and 1E as indicators of rapid progression. To estimate treatment benefit, long-term outcomes were modelled for patients treated with and without tolvaptan based on the TEMPO 3:4 cohort.
METHODS: In the base case, the annual absolute reduction in eGFR decline for tolvaptan versus placebo of 1.2 ml/min/1.73m2 was applied to the predicted rates of eGFR decline in the absence of treatment. Additionally, in a sensitivity analysis based on a post-hoc analysis of TEMPO 3:4, the effect on eGFR decline by subclass 1C, 1D, and 1E was applied. CKD progression and time to ESRD were estimated for both cohorts.
RESULTS: The predicted time to ESRD was longer for all patients in CKD stages 1-3 treated with tolvaptan, with greater estimated absolute benefit when treatment was initiated for patients in early CKD stages (Image).
CONCLUSIONS: The model estimates that patients treated with tolvaptan versus no treatment spend more time in earlier CKD stages and later onset of ESRD. Results were consistent across CKD stages and Mayo subclasses. Findings highlight the potential long-term value of early intervention with tolvaptan in patients at risk of rapid ADPKD progression.